China News Service, Guangzhou, November 16 (Cai Minjie, Lin Jie) The "Organoid Frontier Technology Strategic Cooperation Signing Ceremony" was held in Guangzhou on the 16th.
At the meeting, Guangzhou Huayi Regenerative Technology Co., Ltd., headed by Chen Yeguang, academician of the Chinese Academy of Sciences, signed a series of strategic cooperation agreements with Guangzhou Bio-Island Laboratory, Guangdong Provincial People’s Hospital and Guangzhou Jinyu Medical Laboratory Group Co., Ltd. to accelerate Transformation and application of cutting-edge technologies in the field of biomedicine in China.
The signing of the industry-university-research strategic cooperation agreement will encourage all parties to use their respective advantages to jointly help the creation of organoid biobanks. For example, Huayi Regeneration will give full play to its advantages in organoid technology research, and the Biological Island Laboratory will Taking advantage of its own human resources, Guangdong Provincial People’s Hospital takes advantage of the platform for technological transformation of results, while Golden Mile Medical will cooperate in the fields of organoid bank construction, precision medicine, multi-omics testing and big data analysis to promote the organoid industry research Development.
In recent years, the incidence and mortality of cancer have been increasing.
Wang Hongyang, academician of the Chinese Academy of Engineering and director of the National Liver Cancer Science Center, analyzed: “The five-year survival rate of cancer patients in China is far behind that of developed countries. The anti-cancer situation is very serious. This requires targeting the latest developments in the international medical field. Research and develop new strategies for tumor occurrence and development, early diagnosis and treatment."
According to reports, organoid technology is an important innovative frontier science and technology developed in recent years.
Organoids are micro-organs with three-dimensional structures that are cultivated in an in vitro environment. They are taken from internal organs and tissues. They are highly similar to real tissues and organs through special culture techniques in vitro, and can partially simulate reality. The physiological functions of organs can accurately simulate the internal environment of tumors and the true response to drugs. It is a model for studying tumors and reagents in vitro.
In the future, organoid technology will exert its potential in clinical precision medicine, new drug development, and regenerative medicine, such as drug efficacy testing and drug toxicity screening.
"Science" magazine rated the organoid technology as "Top Ten Breakthroughs in Science and Technology Development" in 2013; "New England Journal of Medicine" rated the technology as the "Preclinical Model of Human Disease" in 2019.
Wang Guilin, director of the Guangzhou Science and Technology Bureau, said that the signing of this cooperation is to continue to promote the development of the entire biomedicine industry chain, enhance the original innovation capability of biomedicine, open up clinical resource channels, and cultivate famous enterprises and famous products.
Pei Gang, an academician of the Chinese Academy of Sciences, mentioned that domestic organoid technology has carried out a lot of work in the fields of stem cells and regenerative biology. However, in terms of market application of results transformation, it still lags behind other countries. China needs to make up for this shortcoming and establish a mechanism for combining production, education and research to target market demand. (Finish)